Pharma Excipients
Excipient for Inhalation
Aero Flo®by Kerry – Inhalation Grade Lactose
Dry Powder Inhalers (DPI) and Lactose
Using a dry powder inhaler (DPI) for drug delivery can provide many advantages over traditional oral delivery of pharmaceuticals. DPI’s also offer advantages over older respiratory delivery methods such as those using nebulizers or pressurized CFC containing…
Read More...
Read More...
Tablettose – MEGGLE’s agglomerated lactose grades for direct compression
General information
Direct compression (DC) tablet manufacture is a popular choice because it provides the least complex, most cost effective process to produce tablets compared to other tablet manufacturing approaches. Manufacturers can blend APIs with excipients and compress, making dosage forms…
Read More...
Read More...
Targeting mucus barrier in respiratory diseases by chemically modified advanced delivery systems
Mucus gel constitutes of heavily cross-linked mucin fibers forming a viscoelastic, dense porous network that coats all the exposed epithelia not covered with the skin. The layer provides protection to the underlying gastrointestinal, respiratory, and female reproductive tracts, in addition to the…
Read More...
Read More...
The Inhalac family by Meggle – See the brochure
MEGGLE’s sieved, milled and micronized alpha-lactose monyhydrate for dry powder inhalation: InhaLac®
General information
The delivery of active pharmaceutical ingredients (APIs) via the lung is becoming increasingly important as ever more patients all over the world suffer from chronic respiratory…
Read More...
Read More...
Solid state of inhalable high dose powders
High dose inhaled powders have received increased attention for treating lung infections. These powders can be prepared using techniques such as spray drying, spray-freeze drying, crystallization, and milling. The selected preparation technique is known to influence the solid state of the powders,…
Read More...
Read More...
Inhaled Therapy for COVID-19: Considerations of Drugs, Formulations and Devices
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent responsible for the COVID-19 pandemic, has outspread at full tilt across the world. Although several effective vaccines continue to be deployed, reliable antiviral treatments have yet to be developed against this…
Read More...
Read More...
Inhalable dry powder mRNA vaccines based on extracellular vesicles
Respiratory diseases are a global burden, with millions of deaths attributed to pulmonary illnesses and dysfunctions. Therapeutics have been developed, but they present major limitations regarding pulmonary bioavailability and product stability. To circumvent such limitations, we developed…
Read More...
Read More...
Lipid-microparticles for pulmonary delivery of active pharmaceutical ingredients: Impact of lipid…
Spray-drying is an extensively used technology for engineering inhalable particles. Important technical hurdles are however experienced when lipid-based excipients (LBEs) are spray-dried. Stickiness, extensive wall deposition, or simply inability to yield a solid product have been associated to the…
Read More...
Read More...
Preparation and evaluation of vancomycin spray dried powders for pulmonary delivery
The aim of the current study was to achieve a dry powder formulation of vancomycin by spray drying whilst evaluating the effect of pH and excipient type and percentage used in formulation on particle characteristics and aerosolization performance. A D-optimal design was applied to optimize the…
Read More...
Read More...
Recent updates in COVID-19 with emphasis on inhalation therapeutics: Nanostructured and targeting…
The current world health threat posed by the novel coronavirus disease of 2019 (COVID-19) calls for the urgent development of effective therapeutic options. COVID-19 needs daunting routes such as nano-antivirals. Hence, the role of nanotechnology is very critical in combating this nano-enemy…
Read More...
Read More...